.jpg)
Mizuho Securities analyst Difei Yang maintained a Buy rating on Aerie Pharma (AERI) on June 14 and set a price target of $77. The company’s shares closed yesterday at $33.84, close to its 52-week low of $31.01.
According to TipRanks.com, Yang is a 5-star analyst with an average return of 9.7% and a 43.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Alder Biopharmaceuticals, and Audentes Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aerie Pharma with a $75.43 average price target, which is a 122.9% upside from current levels. In a report issued on June 11, Canaccord Genuity also maintained a Buy rating on the stock with a $56 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $74.75 and a one-year low of $31.01. Currently, Aerie Pharma has an average volume of 569.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105.
